Form 4: BSX CFO Jonathan Monson's Stock Transactions

Boston Scientific's EVP and CFO, Jonathan Monson, reported the acquisition of common stock from RSU vesting and subsequent disposition for tax obligations.

Summary

• Jonathan Monson, Executive Vice President and Chief Financial Officer of Boston Scientific Corp (BSX), reported stock transactions on August 2, 2025.
• Monson acquired 1,090 shares of common stock through the exercise/conversion of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Concurrently, 528 shares of common stock were disposed of at a price of $105.41 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Monson directly beneficially owns 35,289 shares of Boston Scientific common stock.
• The RSU vesting is part of a pre-existing plan to issue shares in four equal annual installments, which commenced on August 2, 2022.

Sentiment

Score: 7

Explanation: The filing indicates a routine, expected transaction related to executive compensation. The acquisition of shares through RSU vesting is positive as it increases insider ownership, while the sale for tax purposes is a standard practice and not indicative of negative sentiment towards the company.

Positives

• The acquisition of shares by the CFO through RSU vesting indicates continued equity ownership and alignment of interests with shareholders.
• The transaction is a routine vesting of previously granted equity awards, reflecting a planned and expected compensation event.

Negatives

• A portion of the vested shares (528 shares) was sold to cover tax obligations, which is a common practice but results in a slight reduction in direct shareholding.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing, common across all industries for executives receiving equity compensation. It does not provide specific industry context.

Comparison to Industry Standards

• This is a standard insider transaction (Form 4) for equity compensation.
• The practice of withholding shares for tax purposes upon RSU vesting is a common and accepted industry standard for executive compensation across publicly traded companies.

Stakeholder Impact

• Shareholders: The transaction reflects a routine compensation event for a key executive, aligning management's interests with shareholders through equity ownership. The sale of shares for tax purposes is a standard practice and does not indicate a lack of confidence.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units (RSUs) and the subsequent sale of a portion of those shares to cover tax liabilities. Such transactions are standard components of executive compensation and do not typically signal a change in the company's fundamental outlook or performance. The CFO's continued beneficial ownership of a significant number of shares aligns his interests with shareholders. Therefore, this filing alone does not warrant a change in investment thesis; a 'hold' recommendation is appropriate, pending further operational or financial news.

Keywords

Boston Scientific, BSX, Jonathan Monson, Form 4, SEC Filing, Insider Trading, Stock Transactions, Restricted Stock Units, RSU Vesting, CFO, Equity Compensation